KYMR - Conference and earnings call announcements

First-in-human Phase 1 trial evaluating KT-485 (SAR447971) initiated, triggering a $20 million milestone payment from Sanofi WATERTOWN, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the first participant has been dosed in the first-in-human Phase 1 clinical trial evaluating KT-485 (SAR447971), an oral, potent and selective IRAK4 degrader, in adult healthy volunteers and hidradenitis suppurativa (HS) patients. The Phase 1 trial (NCT07629336) is being conducted by the Company's partner Sanofi. Under th

WATERTOWN, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York, NY on June 3, 2026, at 8:10 a.m. ET. A live webcast of the presentation will be available under "News and Events" in the Investors section of the Company's website at www.kymeratx.com. A replay of the webcast will be archived and available following the event.  About Kymera Therapeutics Kymera is a clinical-stage biotechnology company pion

WATERTOWN, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events:  Bank of America 2026 Healthcare Conference in Las Vegas, NV on May 12 at 9:20 a.m. PT; andRBC Capital Markets 2026 Global Healthcare Conference in New York, NY on May 19 at 9:00 a.m. ET. Live webcasts of the presentations will be available under "News and Events" in the Investors section of the Company's website at www.kymeratx.com. Replays of the webcast

WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events:  TD Cowen 46th Annual Healthcare Conference in Boston, MA on March 3 at 9:10 a.m. ET;Leerink Partners Global Healthcare Conference in Miami, FL on March 10 at 11:20 a.m. ET; andBarclays 28th Annual Global Healthcare Conference in Miami, FL on March 12 at 9:30 a.m. ET. In addition, the Company will participate in the UBS Biotech Summit Miami and Jefferies

WATERTOWN, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events:  Guggenheim Emerging Outlook: Biotech Summit 2026 in New York, NY on February 11 at 9:00 a.m. ET; andOppenheimer Virtual 36th Annual Healthcare Life Sciences Conference on February 26 at 2:00 p.m. ET. Live webcasts of the presentations will be available under "News and Events" in the Investors section of the Company's website at www.kymeratx.com. Replays

WATERTOWN, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California on Tuesday, January 13, 2026, at 9:00 a.m. PT/12:00 p.m. ET. Nello Mainolfi, PhD, Founder, President and CEO, will provide an overview of the Company's progress and anticipated milestones for 2026. A live webcast of the presentation and Q&A session will be available under "News and Events" in the Investors section of the Company's website

Data from the KT-621 BROADEN2 Phase 2b AD patient trial expected to be reported by mid-2027 KT-621 BREADTH Phase 2b trial in asthma on track to initiate in 1Q26 Completed dosing in KT-621 BroADen Phase 1b AD trial with data to be reported in December 2025 WATERTOWN, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that it recently initiated dosing in its BROADEN2 Phase 2b clinical trial evaluating KT-621, an oral, highly selective, potent degrader of STAT6, in patients with moderate to severe atopic

WATERTOWN, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events:  Piper Sandler 37th Annual Healthcare Conference in New York, NY on December 2 at 2:30 p.m. ET;Citi 2025 Global Healthcare Conference in Miami, FL on December 3 at 11:15 a.m. ET; andEvercore 8th Annual Healthcare Conference in Coral Gables, FL on December 4 at 8:45 a.m. ET. Live webcasts of the presentations will be available under "News and Events" in th

WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events:  Guggenheim 2nd Annual Healthcare Innovation Conference in Boston, MA on November 10 at 9:00 a.m. ET;UBS 2025 Global Healthcare Conference in Palm Beach, FL on November 10 at 11:45 a.m. ET;Stifel 2025 Healthcare Conference in New York, NY on November 11 at 1:20 p.m. ET;TD Cowen Virtual Immunology & Inflammation Summit on November 13 at 10:30 a.m. ET; andJe

WATERTOWN, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events:  Citi 2025 Biopharma Back to School Conference in Boston, MA on September 3 at 10:30 a.m. ET;Wells Fargo 2025 Healthcare Conference in Boston, MA on September 4 at 9:30 a.m. ET;Morgan Stanley 23rd Annual Global Healthcare Conference in New York, NY on September 9 at 12:20 p.m. ET; andStifel 2025 Virtual Immunology and Inflammation Forum on September 15 at

WATERTOWN, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events:  Jefferies Global Healthcare Conference in New York, NY on June 5 at 8:10 a.m. ET;Goldman Sachs 46th Annual Global Healthcare Conference in Miami, FL on June 10 at 3:20 p.m. ET; andWolfe Research Virtual Biotech Day on June 26, one-on-one meetings only. Live webcasts of the presentations will be available under "News and Events" in the Investors sectio

WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in a fireside chat at the BofA Securities 2025 Healthcare Conference in Las Vegas, NV on May 14, 2025, at 3:40 p.m. PT. A live webcast of the presentation will be available under "News and Events" in the Investors section of the Company's website at www.kymeratx.com. A replay of the webcast will be archived and available following the event.  About Kymera TherapeuticsKymera is a clinical-stage biotechnology company

WATERTOWN, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events: TD Cowen 45th Annual Healthcare Conference in Boston, MA on March 5 at 9:10 a.m. ET;Leerink Partners Global Biopharma Conference in Miami, FL on March 11 at 8:00 a.m. ET;Jefferies Biotech on the Bay Summit in Miami, FL on March 12, one-on-one meetings only; andH.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference on March 27 at 10

WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) --  Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines with biologics-like activity for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events: Guggenheim SMID Cap Biotechnology Conference in New York, NY on February 6 at 10:00 a.m. ET; andOppenheimer 35th Annual Healthcare Life Sciences Conference held virtually on February 11 at 11:20 a.m. ET. Live webcasts of the presentations will be available under "News and Events" in the Investors section of the Company's webs

WATERTOWN, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines with biologics-like activity for immunological diseases, today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California on Tuesday, January 14, 2025, at 9:00 a.m. PT/12:00 p.m. ET. Nello Mainolfi, PhD, Founder, President and CEO, will provide an overview of the Company's progress and anticipated milestones for 2025. A live webcast of the presentation and Q&A session will be available under "News and Events" in the Invest

WATERTOWN, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats at the following upcoming investor events: Piper Sandler 36th Annual Healthcare Conference in New York, NY on December 3 at 1:00 p.m. ET; and7th Annual Evercore ISI HealthCONx Conference in Coral Gables, FL on December 4 at 4:15 p.m. ET. Live webcasts of the presentations will be available under "News and Events" in the Investors section of the Company's website at www.kymeratx.com. Replays of the

WATERTOWN, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats at the following upcoming investor events: Guggenheim Inaugural Healthcare Innovation Conference in Boston, MA on November 12 at 10:00 a.m. ET;J.P. Morgan Equity Opportunities Forum in Miami, FL on November 14, one-on-one meetings only;Stifel 2024 Healthcare Conference in New York, NY on November 18 at 11:30 a.m. ET;6th Annual Wolfe Research Healthcare Conference in New York, NY on November 19

WATERTOWN, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats and presentations at the following upcoming investor events: Wells Fargo 2024 Healthcare Conference in Boston, MA on September 4 at 3:00 p.m. ET;Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY on September 5 at 3:20 p.m. ET;H.C. Wainwright 26th Annual Global Investment Conference in New York, NY on September 9 at 8:00 a.m. ET; and2024 Cantor Fitzgerald Global Healthcar

WATERTOWN, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats at the following upcoming investor events: Jefferies 2024 Global Healthcare Conference in New York, NY on June 5 at 11:30 a.m. ET; andGoldman Sachs 45th Annual Global Healthcare Conference in Miami, FL on June 11 at 2:40 p.m. ET. Live webcasts of the presentations will be available under "News and Events" in the Investors section of the Company's website at www.kymeratx.com. Replays of the webcasts

WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats at the following upcoming investor events: BofA Securities 2024 Health Care Conference in Las Vegas, NV on May 15 at 4:20 p.m. PT; andTD Cowen 5th Annual Oncology Innovation Virtual Summit on May 28 at 1:30 p.m. ET. Live webcasts of the presentations will be available under "News and Events" in the Investors section of the Company's website at www.kymeratx.com. Replays of the webcasts will be archi

WATERTOWN, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats at the following upcoming investor events: TD Cowen 44th Annual Healthcare Conference in Boston, MA on March 6 at 12:50 p.m. ET;Leerink Partners Global Biopharma Conference in Miami, FL on March 12 at 3:40 p.m. ET;Jefferies Biotech on the Bay Summit in Miami, FL on March 13, the Company will host one-on-one meetings only; andH.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Con

WATERTOWN, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced the Company will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, California on Tuesday, January 9, 2024, at 9:00 a.m. PT/12:00 p.m. ET. Nello Mainolfi, Ph.D., Founder, President and CEO, will provide an overview of the Company's progress and anticipated milestones for 2024. A live webcast of the presentation and Q&A session will be available under the "Events and Presentations" section of the Investors page on the Co

WATERTOWN, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation, today announced that the Company will participate at the following upcoming investor events: TD Cowen 7th Annual Virtual Fall Oncology Innovation Summit on November 3 at 2:00 p.m. ET;UBS Biopharma Conference in Miami, FL on November 8 at 10:30 a.m. ET;Stifel 2023 Healthcare Conference in New York, NY on November 15 at 2:25 p.m. ET;Piper Sandler 35th Annual Healthcare Conference in New York, NY on November 28 at 12:30 p.m. ET; andEvercore ISI 6th Annual HealthCONx Confere

WATERTOWN, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company's management team will attend and participate in presentations at the following upcoming investor events: Wells Fargo 2023 Healthcare Conference in Boston, MA on September 6 at 8:45 a.m. ET;Morgan Stanley 21st Annual Global Healthcare Conference in New York, NY on September 12 at 4:15 p.m. ET; andH.C. Wainwright 25th Annual Global Investment Conference in New York, NY on September 13 at 10:00 a.m. ET. Live webcasts of the pr

WATERTOWN, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company's management team will attend the following upcoming investor event: Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, CA on June 14 at 3:20 p.m. PT (6:20 p.m. ET) A live webcast of the fireside chat will be available under the "Events and Presentations" section of the Investors page on the Company's website at www.kymeratx.com. A replay of the webcast will be archived and available following the even

WATERTOWN, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company's management team will attend the following upcoming investor events: Cowen 43rd Annual Health Care Conference in Boston, MA on March 6-8, 2023; Nello Mainolfi, PhD, Founder, President and CEO, will participate in a fireside chat on March 6 at 10:30 AM ET, and the Company will host 1x1 meetings Jefferies Biotech on the Bay Summit in Miami, FL on March 16-17, 2023; the Company will host 1x1 meetings only A live webcas

WATERTOWN, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the Company will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California on Tuesday, January 10, 2023, at 9:00 AM PST. Nello Mainolfi, PhD, Co-Founder, President and CEO, will provide an overview of the Company's progress and anticipated milestones for 2023. A live webcast will be available under the "Events and Presentations" section of the Investors page on the Company's website at www.kymeratx.com. A r

WATERTOWN, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today shared webcast information for the virtual investor event that the Company will host on December 14, 2022, from 8:00-9:30 AM ET. The Company's management team will provide a clinical update on Part C of the Phase 1 clinical trial evaluating its IRAK4 degrader KT-474 in patients with either hidradenitis suppurativa or atopic dermatitis, as well as an update on its oncology pipeline. To join the webcast, please visit this link, or the "Events & Presentat

WATERTOWN, Mass., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, announced that Nello Mainolfi, PhD, Co-Founder, President and CEO, will participate in Fireside Chats at the following upcoming investor conferences: 2022 Wells Fargo Healthcare Conference: September 7th at 1:20 p.m. ETMorgan Stanley 20th Annual Global Healthcare Conference: September 14th at 8:00 a.m. ET2022 Guggenheim Nantucket Therapeutics Conference: September 28th at 2:15 p.m. ET Presentation webcasts will be available under "Events and Presentations"

WATERTOWN, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will participate in the following upcoming virtual investor conferences:   Cowen & Co. 42nd Annual Health Care Conference 2022: Fireside Chat with Nello Mainolfi, PhD, Co-Founder, President and CEO on March 8th at 9:50 a.m. ET  Guggenheim Healthcare Talks | Targeted Protein Degradation Day: Fireside Chat with Nello Mainolfi, PhD, Co-Founder, President and CEO on March 16th at 8:00a.m. ET   Presentation webcasts will be avai

WATERTOWN, Mass., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will participate in the following upcoming virtual investor conferences: B. Riley Securities Oncology Investor Conference: Fireside Chat with Chief Medical Officer, Jared Gollob, MD on January 28th at 10:30 a.m. ETGuggenheim Healthcare Talks | Oncology Day: Fireside Chat with Chief Medical Officer, Jared Gollob, MD and Nello Mainolfi, PhD, Co-Founder, President and CEO on February 10th at 9:30 a.m. ETBIO CEO and Investor Conf

WATERTOWN, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the Company will present at the virtual 40th Annual J.P. Morgan Healthcare Conference at 9:00 a.m. ET / 6:00 a.m. PT on Tuesday, January 11, 2022. Nello Mainolfi, PhD, Co-Founder, President and CEO of Kymera, will provide an overview of the Company's progress and anticipated milestones for 2022 and beyond. A live webcast of the presentation can be accessed under "Events and Presentations" in the Investors section of the Company's website at w

Proof-of-mechanism and proof-of-biology established for first-in-class, oral IRAK4 degrader, KT-474, in Single Ascending Dose portion of Phase 1 healthy volunteer trial with up to 96% degradation in blood and up to 97% inhibition of cytokines FDA clearance of Investigational New Drug Application for first-in-class STAT3 degrader, KT-333R&D Day Webinar scheduled for December 16, 2021, with first disclosures of KT-474 Multiple Ascending Dose data, new degrader programs in development and new platform expansions WATERTOWN, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to del

WATERTOWN, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will participate in several upcoming virtual investor conferences: UBS: Panel discussion: "TPD from Concept to Clinic: What Have We Learned So Far From Clinical Data?" on November 1, 2021 at 11:00 a.m. ET.Credit Suisse 30th Annual Virtual Healthcare Conference: Fireside chat on November 11, 2021 at 1:00 p.m. ET.Stifel 2021 Virtual Healthcare Conference: Fireside chat on November 15, 2021 at 8:40 a.m. ET.Guggenheim Healthcare

WATERTOWN, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will present at two upcoming investor conferences: Morgan Stanley 19th Annual Global Healthcare Conference: a fireside chat webcast will be available live on Thursday, September 9, 2021 at 1:15 p.m. ET.H.C. Wainwright 23rd Annual Global Investment Conference: an on demand webcast presentation will be available beginning on Monday, September 13, 2021 at 7:00 a.m. ET. Presentation webcasts will be available under "Events and

WATERTOWN, Mass., June 02, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will participate in a virtual fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on Wednesday, June 9 at 4:40 p.m. ET. A live webcast of the event will be available under "Events and Presentations" in the Investors section of the Company's website at www.kymeratx.com. A replay of the webcast will be archived and available for one month following the event. About Kymera TherapeuticsKymera Therapeutics

WATERTON, Mass., May 04, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will present at the upcoming investor conferences: BofA Securities 2021 Virtual Healthcare Conference on Thursday, May 13 at 3:30 p.m. ETUBS Global Healthcare Virtual Conference on Tuesday, May 25 at 12:00 p.m. ET A live webcast of each event will be available under "Events and Presentations" in the Investors section of the Company's website at www.kymeratx.com. Archived webcast replays of the presentations will also be availa

WATERTOWN, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will participate in upcoming investor conferences: Cowen 41st Annual Health Care Conference: a panel discussion will be available live to conference attendees on Wednesday, March 3 at 11:40 a.m. ET.H.C. Wainwright Global Life Sciences Conference: a webcast presentation will be available on demand beginning Tuesday, March 9 at 7:00 a.m. ET.Guggenheim Targeted Protein Degradation Day: a panel discussion will be webcast live on Tuesday, March

WATERTOWN, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will present at two upcoming investor conferences: Guggenheim Healthcare Talks 2021 Oncology Day on Thursday, February 11 at 1:30 p.m. ETBMO BioPharma Spotlight Series: “Proteins - Degraders and Other Next Gen Technologies” on Thursday, February 18 at 10:30 a.m. ET A live webcast of each event will be available under "Events and Presentations" in the Investors section of the Company's website at www.kymeratx.com. Archived webcast replays

WATERTOWN, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will present at the virtual 39th Annual J.P. Morgan Healthcare Conference at 2:00 p.m. ET on Thursday, January 14, 2021. Nello Mainolfi, PhD, Co-Founder, President and CEO of Kymera, will provide an overview of the Company’s progress and anticipated milestones for 2021. A live webcast of the presentation can be accessed under "Events and Presentations" in the Investors section of the Company's website at www.kymeratx.com. An archived webca